Aspects biologiques de la voie JAK/STAT dans les néoplasmes myéloprolifératifs classiques négatifs pour BCR-ABL

Tefferi, 2008, Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms, Leukemia, 22, 14, 10.1038/sj.leu.2404955

Rumi, 2014, JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes, Blood, 123, 1544, 10.1182/blood-2013-11-539098

Klampfl, 2013, Somatic mutations of calreticulin in myeloproliferative neoplasms, The New England journal of medicine, 369, 2379, 10.1056/NEJMoa1311347

Yamaoka, 2004, The Janus kinases (Jaks), Genome Biol, 5, 253, 10.1186/gb-2004-5-12-253

Hammaren, 2015, ATP binding to the pseudokinase domain of JAK2 is critical for pathogenic activation, Proc Natl Acad Sci U S A, 112, 4642, 10.1073/pnas.1423201112

Vainchenker, 2013, JAK/ STAT signaling in hematological malignancies, Oncogene, 32, 2601, 10.1038/onc.2012.347

James, 2005, A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera, Nature, 434, 1144, 10.1038/nature03546

Bandaranayake, 2012, Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F, Nat Struct Mol Biol, 19, 754, 10.1038/nsmb.2348

Yan, 2012, Critical requirement for Stat5 in a mouse model of polycythemia vera, Blood, 119, 3539, 10.1182/blood-2011-03-345215

Duek, 2014, Loss of Stat1 decreases megakaryopoiesis and favors erythropoiesis in a JAK2-V617F-driven mouse model of MPNs, Blood, 123, 3943, 10.1182/blood-2013-07-514208

Grisouard, 2015, Deletion of Stat3 in hematopoietic cells enhances thrombocytosis and shortens survival in a JAK2-V617F mouse model of MPN, Blood, 125, 2131, 10.1182/blood-2014-08-594572

Lacout, 2006, JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis, Blood, 108, 1652, 10.1182/blood-2006-02-002030

Tiedt, 2008, Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice, Blood, 111, 3931, 10.1182/blood-2007-08-107748

Hasan, 2013, JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFNalpha, Blood, 122, 1464, 10.1182/blood-2013-04-498956

Li, 2014, JAK2V617F homozygosity drives a phenotypic switch in myeloproliferative neoplasms, but is insufficient to sustain disease, Blood, 123, 3139, 10.1182/blood-2013-06-510222

Scott, 2006, Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia, Blood, 108, 2435, 10.1182/blood-2006-04-018259

Scott, 2011, The JAK2 exon 12 mutations: a comprehensive review, American journal of hematology, 86, 668, 10.1002/ajh.22063

Passamonti, 2011, Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations, Blood, 117, 2813, 10.1182/blood-2010-11-316810

Pikman, 2006, MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia, PLoS medicine, 3, 10.1371/journal.pmed.0030270

Pardanani, 2006, MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients, Blood, 108, 3472, 10.1182/blood-2006-04-018879

Defour, 2015, Oncogenic activation of MPL/ thrombopoietin receptor by 17 mutations at W515: implications for myeloproliferative neoplasms, Leukemia, 10.1038/leu.2015.271

Ding, 2004, Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin, Blood, 103, 4198, 10.1182/blood-2003-10-3471

Cabagnols, 2016, lanotto JC, et al. Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients, Blood, 127, 333, 10.1182/blood-2015-07-661983

Milosevic Feenstra, 2016, Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms, Blood, 127, 325, 10.1182/blood-2015-07-661835

Vannucchi, 2008, Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia, Blood, 112, 844, 10.1182/blood-2008-01-135897

Guglielmelli, 2007, Anaemia characterises patients with myelofibrosis harbouring Mpl mutation, British journal of haematology, 137, 244, 10.1111/j.1365-2141.2007.06565.x

Broseus, 2014, Presence of calreticulin mutations in JAK2-negative polycythemia vera, Blood, 124, 3964, 10.1182/blood-2014-06-583161

Lundberg, 2014, Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms, Blood, 123, 2220, 10.1182/blood-2013-11-537167

Cabagnols, 2015, Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: relevance for disease evolution, Leukemia, 29, 249, 10.1038/leu.2014.270

Marty, 2016, Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis, Blood, 127, 1317, 10.1182/blood-2015-11-679571

Balligand, 2016, Pathologic activation of thrombopoietin receptor and JAK2-STAT5 pathway by frameshift mutants of mouse calreticulin, Leukemia, 10.1038/leu.2016.47

Chachoua, 2016, Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants, Blood, 127, 1325, 10.1182/blood-2015-11-681932

Araki, 2016, Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms, Blood, 127, 1307, 10.1182/blood-2015-09-671172

Tefferi, 2014, Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact, Leukemia, 28, 1568, 10.1038/leu.2014.83

Oh, 2010, Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms, Blood, 116, 988, 10.1182/blood-2010-02-270108

Velazquez, 2002, Cytokine signaling and hematopoietic homeostasis are disrupted in Lnk-deficient mice, J Exp Med, 195, 1599, 10.1084/jem.20011883

Rampal, 2014, Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis, Blood, 123, e123, 10.1182/blood-2014-02-554634

Mahfoudhi, 2015, Properties and biological roles of TET proteins during embryogenesis and in hematopoiesis, Medecine sciences : M/S, 31, 268, 10.1051/medsci/20153103012

Pronier, 2011, Inhibition of TET2-mediated conversion of 5-methylcytosine to 5-hydroxymethylcytosine disturbs erythroid and granulo-monocytic differentiation of human hematopoietic progenitors, Blood, 10.1182/blood-2010-12-324707

Quivoron, 2011, TET2 Inactivation Results in Pleiotropic Hematopoietic Abnormalities in Mouse and Is a Recurrent Event during Human Lymphomagenesis, Cancer cell, 20, 25, 10.1016/j.ccr.2011.06.003

Busque, 2012, Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis, Nat Genet, 44, 1179, 10.1038/ng.2413

Ortmann, 2015, Effect of mutation order on myeloproliferative neoplasms, The New England journal of medicine, 372, 601, 10.1056/NEJMoa1412098

Challen, 2012, Dnmt3a is essential for hematopoietic stem cell differentiation, Nat Genet, 44, 23, 10.1038/ng.1009

Score, 2012, Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasms, Blood, 119, 1208, 10.1182/blood-2011-07-367243

Gelsi-Boyer, 2009, Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia, British journal of haematology, 145, 788, 10.1111/j.1365-2141.2009.07697.x

Vannucchi, 2013, Mutations and prognosis in primary myelofibrosis, Leukemia, 27, 1861, 10.1038/leu.2013.119

Abdel-Wahab, 2013, Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo, J Exp Med, 210, 2641, 10.1084/jem.20131141

Figueroa, 2010, Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation, Cancer cell, 18, 553, 10.1016/j.ccr.2010.11.015

Yoshida, 2011, Frequent pathway mutations of splicing machinery in myelodysplasia, Nature, 478, 64, 10.1038/nature10496

Harutyunyan, 2011, p53 lesions in leukemic transformation, The New England journal of medicine, 364, 488, 10.1056/NEJMc1012718

Klampfl, 2011, Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression, Blood, 118, 167, 10.1182/blood-2011-01-331678

Olcaydu, 2009, A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms, Nat Genet, 41, 450, 10.1038/ng.341

Koren, 2014, Genetic variation in human DNA replication timing, Cell, 159, 1015, 10.1016/j.cell.2014.10.025

Soler, 2015, The JAK2 46/1 haplotype does not predispose to CALR-mutated myeloproliferative neoplasms, Ann Hematol, 94, 789, 10.1007/s00277-014-2266-y

Tapper, 2015, Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms, Nat Commun., 6, 6691, 10.1038/ncomms7691

Harutyunyan, 2016, Germline RBBP6 mutations in familial myeloproliferative neoplasms, Blood, 127, 362, 10.1182/blood-2015-09-668673

Saliba, 2015, Germline duplication of ATG2B and GSKIP predisposes to familial myeloid malignancies, Nat Genet, 47, 1131, 10.1038/ng.3380

Pasquier, 2014, Myeloproliferative neoplasms: JAK2 signaling pathway as a central target for therapy, Clin Lymphoma Myeloma Leuk., 14, S23, 10.1016/j.clml.2014.06.014

Verger, 2015, Clinical and molecular response to interferon-alpha therapy in essential thrombocythemia patients with CALR mutations, Blood, 126, 2585, 10.1182/blood-2015-07-659060